On October 16, 2019, Shanghai Luoqi Biology and Professor Yang Zhi of the Department of Nuclear Medicine of Peking University Cancer Hospital cooperated to publish a research paper entitled "Construction of anti-hPD-L1 HCAb Nb6 and in situ 124I labeling for noninvasive detection of PD-L1 expression in human bone sarcoma" in BIOCONJUGATE CHEMISTRY, and invited to publish it as a cover article.

The signal channel of programmed cell death protein-1/programmed cell death ligand - 1 (PD-1/PD-L1) is a hot target of tumor immunotherapy. Clinical trials showed that the expression of PD-L1 in tumor was related to the clinical stage and poor prognosis of patients. The detection of tumor cell PD-L1 is helpful to screen the preponderant population of anti-PD-1/PD-L1 immunotherapy and evaluate its prognosis. The advanced molecular imaging technology represented by positron emission computed tomography (PET/CT) provides a powerful means to detect the expression of multiple markers, which can achieve non-invasive, dynamic and overall three-dimensional display of the expression and distribution of markers. It is particularly important to emphasize that nanoantibodies have been selected for live imaging in this study. Because of their small molecular weight and fast biological distribution, nanoantibodies can be imaged in a short time after injection of drugs, which can greatly increase the convenience of patients and be used for targeted therapy imaging.

The PET/CT molecular imaging method targeting PD-L1 established in this study has realized real-time and non-invasive monitoring of PD-L1 expression in systemic lesions. The successful implementation of this work has laid a solid foundation for the development and application of subsequent PD-L1 clinical products. The two sides will continue to cooperate, complement each other's advantages, continue to deepen relevant research, and realize the development and development of human real-time and non-invasive monitoring products as soon as possible.